Where is the manufacturer of Eculizumab?

Eculizumab (Eculizumab) is manufactured by Alexion Pharmaceuticals, Inc. Eculizumab is approved in the United States, the European Union, Japan and China for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and certain rare inherited bleeding disorders, such as classic hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) and neuromyelitis optica (NMOSD).

Eculizumab is the firstC5 complement inhibitor. The drug works by inhibiting the C5 protein in the terminal complement cascade, which is part of the body's immune system. When activated in an uncontrolled manner, the terminal complement cascade overreacts, causing the body to attack its own healthy cells. Eculizumab is administered intravenously every two weeks after the initial dosing period. Eculizumab is not indicated for the treatment of patients with Shiga toxin E. coli -associated hemolytic uremic syndrome. If a patient develops an allergic reaction during treatment, the doctor may slow down or stop the infusion.

The generic drug Eculizumab has been launched in China and is covered by medical insurance. It is only available for reimbursement to eligible patients. The specification is 300mg (30ml) and the price per box may be more than 3,000 yuan. It is understood that the price of each box of the original Eculizumab drug sold overseas is more than 6,000 US dollars (the price may fluctuate due to the exchange rate). The ingredients of the original drug sold at home and abroad are basically the same, and the price of the original drug is still relatively expensive. There are currently no generic versions of eculizumab available on the market. For specific overseas drug prices and drug information, please consult Yaode Medical Consultant.